Abstract 170P
Background
The KRAS gene plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). This study aimed to investigate the frequency of KRAS mutations in patients with PDAC.
Methods
From 2020 to 2023, we retrospectively analyzed the KRAS status in 45 patients with PDAC. The distribution of clinical stages and the frequency of other mutations such as NRAS and BRCA2 were also evaluated.
Results
Among 45 patients, 30 (66.7%) had KRAS mutations, with the most frequent being G12D (50%), followed by G12V (26.6%). Q61K, G12A, A146T, G12R, and G12C mutations were less common. One patient with G12V mutation also had a BRCA2 mutation. In the mutated KRAS (mKRAS) group, 13 patients (43.3%) had metastatic disease, 12 (40%) had localized disease, and 5 (16.6%) had locally advanced disease. In the wild-type KRAS (wtKRAS) group, which consisted of 15 patients (33.3%), 7 (46.7%) had metastatic disease, 5 (33.3%) had localized disease, and 3 (20%) had locally advanced disease. One patient with wtKRAS also had a germline BRCA2 mutation. The distribution of clinical stages did not differ significantly between mKRAS and wtKRAS groups. NRAS mutation analysis was conducted in 41 patients, and no mutations were detected.
Conclusions
Our study revealed a high frequency of wtKRAS in patients with PDAC. Further investigation is needed to expound the clinical significance of KRAS status in this patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract